T. Rowe Price Associates
RCUS icon

T. Rowe Price Associates’s Arcus Biosciences RCUS Stock Holding History

T. Rowe Price Associates’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.75M Buy
89,202
+13,386
+18% +$331K ﹤0.01% 1856
2026
Q1 		$1.64M Buy
75,816
+17,167
+29% +$371K ﹤0.01% 1922
2025
Q4 		$1.4M Buy
58,649
+9,307
+19% +$190K ﹤0.01% 1927
2025
Q3 		$672K Buy
49,342
+4,973
+11% +$51.7K ﹤0.01% 2251
2025
Q2 		$362K Buy
44,369
+10,298
+30% +$88K ﹤0.01% 2455
2025
Q1 		$268K Buy
34,071
+3,123
+10% +$36.2K ﹤0.01% 2518
2024
Q4 		$461K Sell
30,948
-6,265
-17% -$102K ﹤0.01% 2317
2024
Q3 		$569K Buy
37,213
+715
+2% +$11.3K ﹤0.01% 2195
2024
Q2 		$556K Buy
36,498
+1,734
+5% +$28K ﹤0.01% 2151
2024
Q1 		$657K Buy
34,764
+1,906
+6% +$33K ﹤0.01% 2096
2023
Q4 		$628K Buy
32,858
+1,645
+5% +$26.3K ﹤0.01% 2083
2023
Q3 		$561K Sell
31,213
-250,407
-89% -$5.03M ﹤0.01% 2053
2023
Q2 		$5.72M Buy
281,620
+2,090
+0.7% +$39.8K ﹤0.01% 1166
2023
Q1 		$5.1M Sell
279,530
-226,217
-45% -$4.32M ﹤0.01% 1180
2022
Q4 		$10.5M Buy
505,747
+481,848
+2,016% +$13.3M ﹤0.01% 1047
2022
Q3 		$626K Buy
23,899
+6,198
+35% +$164K ﹤0.01% 2011
2022
Q2 		$449K Sell
17,701
-1,736
-9% -$42.5K ﹤0.01% 2264
2022
Q1 		$613K Buy
19,437
+1,622
+9% +$54.3K ﹤0.01% 2249
2021
Q4 		$721K Sell
17,815
-769
-4% -$29.8K ﹤0.01% 2198
2021
Q3 		$648K Sell
18,584
-39
-0.2% -$1.21K ﹤0.01% 2250
2021
Q2 		$511K Sell
18,623
-2,612
-12% -$74.6K ﹤0.01% 2388
2021
Q1 		$596K Sell
21,235
-9
-0% -$313 ﹤0.01% 2295
2020
Q4 		$551K Buy
21,244
+9,842
+86% +$238K ﹤0.01% 2202
2020
Q3 		$195K Buy
+11,402
New +$255K ﹤0.01% 2427
2019
Q1 		– Sell
-387,312
Closed -$4.17M – 2560
2018
Q4 		$4.17M Sell
387,312
-1,078
-0.3% -$12.6K ﹤0.01% 1425
2018
Q3 		$5.41M Sell
388,390
-255,700
-40% -$3.26M ﹤0.01% 1445
2018
Q2 		$7.88M Sell
644,090
-11,348
-2% -$178K ﹤0.01% 1385
2018
Q1 		$10.1M Buy
+655,438
New +$10.9M ﹤0.01% 1332

Other funds holding RCUS

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

T. Rowe Price Associates's RCUS Position: Q2 2026 in Review

T. Rowe Price Associates increased its Arcus Biosciences (RCUS) stake by 18% in Q2 2026, buying an estimated $331K and bringing the position to 89,202 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #1856.

T. Rowe Price Associates first reported a position in RCUS in Q1 2018 and has held it in 28 quarters since. The position peaked at $10.5M in Q4 2022. 232 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • T. Rowe Price Associates held 89,202 shares of Arcus Biosciences worth $2.75M as of Q2 2026.
  • T. Rowe Price Associates bought 13,386 Arcus Biosciences shares in Q2 2026, an estimated $331K.
  • Arcus Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1856 holding.
  • T. Rowe Price Associates first reported a position in Arcus Biosciences in Q1 2018 and has held it in 28 quarters since.
  • T. Rowe Price Associates's Arcus Biosciences position peaked at $10.5M in Q4 2022.
  • 232 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.